Annual return of 118.79% - See How Click here now!
For more info: http://www.realpennies.com/otc/nwbo
(OTCBB:NWBO) Northwest Biotherapeutics, Inc.
BETHESDA, Md. -- Northwest Biotherapeutics, Inc. , recently announced that it has entered into a Loan Agreement and Promissory Note with SDS Capital Group SPC, Ltd . Under the Note, SDS has loaned the Company US$1,000,000. The Note is an unsecured obligation of the Company and accrues interest at the rate of 12% per year. The term of the Note is six months, with a maturity date of April 1, 2009. The Note may not be prepaid without the consent of SDS. The Note contains customary representations, warranties, and covenants. In connection with the Note, the Company has issued to SDS a warrant to purchase up to 299,046 shares of the Company's common stock at an exercise price equal to US $0.53 per share, which was the closing price of the Company's common stock on the AIM market of the London Stock Exchange on October 1, 2008. The Investment Warrant is exercisable immediately, and expires 5 years from the date of issuance.
Profile for Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer. Its technology platforms include dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company's primary products include DCVax-Prostate for the treatment of hormone independent nonmetastatic prostate cancer, which cleared Phase III clinical trial; DCVax-Brain, which is in Phase II clinical trial, for the treatment of Glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-sma...
Detailed Description...
LAST $0.88 USD
Read our full disclaimer at: http://www.realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.
CONTACT: RealPennies Tel: +1 800 940 6559 e-mail: info@realpennies.com WWW: http://www.realpennies.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
